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Abstract: Thousands of mothers are at risk of transmitting mitochondrial diseases to their offspring each year, with 
the most severe form of these diseases being fatal [1]. With no cure, transmission prevention is the only current 
hope for decreasing the disease incidence. Current methods of prevention rely on low mutant maternal mitochon-
drial DNA levels, while those with levels close to or above threshold (>60%) are still at a very high risk of transmis-
sion [2]. Two novel approaches may offer hope for preventing and treating mitochondrial disease: mitochondrial 
replacement therapy, and CRISPR/Cas9. Mitochondrial replacement therapy has emerged as a promising tool that 
has the potential to prevent transmission in patients with higher mutant mitochondrial loads. This method is the 
subject of many ethical concerns due its use of a donor embryo to transplant the patient’s nuclear DNA; however, it 
has ultimately been approved for use in the United Kingdom and was recently declared ethically permissible by the 
FDA. The leading-edge CRISPR/Cas9 technology exploits the principles of bacterial immune function to target and 
remove specific sequences of mutated DNA. This may have potential in treating individuals with disease caused 
by mutant mitochondrial DNA. As the technology progresses, it is important that the ethical considerations herein 
emerge and become more established. The purpose of this review is to discuss current research surrounding the 
procedure and efficacy of the techniques, compare the ethical concerns of each approach, and look into the future 
of mitochondrial gene replacement therapy.
Keywords: CRISPR-Cas systems, mitochondrial diseases, mitochondrial replacement therapy, nuclear transfer, 
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Introduction
Mitochondrial diseases are among the most 
devastating inheritable diseases, with the most 
severe forms causing death shortly after birth 
[1]. While there is currently no cure for mito-
chondrial diseases, advances in science have 
provided avenues for prevention of disease 
transmission. Preimplantation genetic diagno-
sis (PGD), one such method of mitochondrial 
disease prevention, is a technique that screens 
cells taken from in vitro fertilization (IVF) embry-
os prior to uterine implantation to select for 
healthy embryos. Armed with the knowledge of 
the mitochondrial genotype, parents can make 
informed decisions about the pregnancy. 
Specifically, PGD has been shown to significant-
ly increase the probability of producing healthy 
offspring for heteroplasmic carriers of mito-
chondrial DNA (mtDNA) mutations. However, 
PGD is not a valuable test for all patients. While 
it provides information about the mtDNA, it 
offers no intervention when the mtDNA is found 
to be mutant, as is often the case with homo-
plasmic carriers or heteroplasmic carriers 
close to the disease threshold [2]. For this rea-
son, the field of mitochondrial disease preven-
tion will be limited until other interventions are 
ready for clinical use.
In recent years, a novel method of mtDNA 
replacement therapy (MRT) has emerged as a 
promising approach to preventing mitochondri-
al disease transmission [3]. This technique 
uses an enucleated donor embryo as a cyto-
plasmic environment for the nuclei of parent 
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germ cells, thereby preventing the transmission 
of mitochondria from the parent cells. Here, we 
discuss recent findings, results, and efficacies 
of the three main variations of MRT being stud-
ied. While MRT shows much potential, there are 
serious ethical concerns surrounding this 
approach, which may put its future on dubious 
ground.
Additionally, we will discuss the recent studies 
of CRISPR/Cas9 as an effective method of edit-
ing genes and treating disease in animal mod-
els, and apply these findings to potential cura-
tive or therapeutic future treatments of mito-
chondrial disease.
Background
Mitochondrial disease genetics
Mitochondrial disorders encompass a wide 
array of genetic mutations and resulting dis-
ease characteristics, ranging in severity from 
asymptomatic to fatal within the first few years 
of life [4, 5]. There is no cure for mitochondrial 
disease, so treatment is mostly palliative and 
symptomatic. The wide-ranging manifestations 
and clinical presentations of these disorders 
has made it difficult to ascertain the true preva-
lence and impact on the population. Recent 
epidemiological studies with detailed pedigree 
analysis have determined that mitochondrial 
disease is more common than previously 
thought, with a prevalence of 16.5 per 100,000 
children and young adults, making it one of the 
most common inherited neuromuscular disor-
ders [6].
mtDNA is exclusively maternally inherited. 
Various mutations of mtDNA result in mitochon-
drial dysfunction, which can have serious con-
sequences for tissues with high metabolic 
demand, such as the brain, heart, muscle, and 
central nervous system. Mitochondrial dysfunc-
tion often manifests as multi-organ disease. 
The wide array of clinical features of these dis-
eases can include: central and peripheral ner-
vous system abnormalities including seizures, 
stroke-like episodes, deafness, and visual 
impairment; myopathies such as external oph-
thalmoplegia and proximal limb myopathy; 
hepatic stenosis and liver failure; renal dys-
function including tubular acidosis and Fanconi 
syndrome; gastrointestinal disturbances such 
as gastroparesis and pancreatitis; and finally, 
endocrine dysfunctions including the hypose-
cretion of thyroid, parathyroid, and hypothalam-
ic hormones, as well as insulin and adrenaline 
[4, 7-9]. Mothers carrying the mutated mtDNA 
can be either homoplasmic (containing only 
mutated mtDNA), in which case the symptoms 
are usually severe, or heteroplasmic (contain-
ing both mutated and wild-type mtDNA), where 
patients present with symptoms ranging from 
nearly nonexistent to moderate. While the clini-
cal features of mitochondrial disease are vast, 
the severity of phenotypic effects depends on 
the proportion of mitochondria that carry the 
mutation [4, 10].
While a mother may present as asymptomatic 
because she contains just a small percentage 
of mutant mtDNA, she only passes on a small 
number of mtDNA molecules to her offspring; 
therefore, there is a chance that she will pass 
on a vastly different proportion of mutant 
mtDNA. Large shifts in this proportion from 
mother to offspring, also known as genetic bot-
tlenecking of mtDNA, can result in phenotypic 
effects if the threshold level of mutant mtDNA 
is met [11]. The threshold level is the minimum 
critical number of mitochondria with mutant 
mtDNA required to cause mitochondrial dys-
function in a tissue. This number is usually 
between 70-90%, and is determined by the 
metabolic need of the tissue [11]. 
In order to diagnose mitochondrial disease, a 
very detailed family history is required to seek 
out subtle clues demonstrating a maternal line 
of inheritance [11]. Due to the variable expres-
sion of these conditions, it may not always be 
obvious that a woman is a carrier of a mtDNA 
mutation. Advances in research and medicine 
over the past several decades have allowed the 
complete sequence of human mtDNA to be elu-
cidated [5]. Genetic testing for the most com-
mon mutations in mtDNA are now widely avail-
able in diagnostic laboratories and a simple 
blood test can reveal the most common muta-
tions associated with the most prevalent clini-
cal syndromes. Despite these advances in 
detecting mtDNA mutations, it is still difficult to 
provide women with accurate preconception 
genetic counseling. While many large-scale 
deletions are infrequent, point mutations and 
heteroplasmy are much more common and 
make it difficult to predict transmission [12]. A 
heteroplasmic female carrier of a mtDNA muta-
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tion could pass on to offspring the same pro-
portion of mutant to wild-type mtDNA, a higher 
proportion, or even a lower proportion [11]. Due 
to the unpredictability of transmission, it is not 
possible to offer accurate preconception advice 
to women who carry heteroplasmic disease-
causing point mutations. Given the lack of cura-
tive treatments for mitochondrial diseases and 
the limitations of genetic counseling and prena-
tal diagnoses, research has focused on pre-
venting the transmission of mutated mtDNA. 
While this is an improvement, it is still inade-
quate for dealing with mitochondrial disease, 
and future research must focus on developing 
curative and therapeutic treatments.
CRISPR/Cas9
The possibilities of gene editing expanded vast-
ly in 2012 upon the discovery of the CRISPR/
Cas9 complex, which is short for “clustered 
regularly-interspaced short palindromic re- 
peats” and “CRISPR-associated protein 9”, 
respectively [13]. Prokaryotes have CRISPR 
segments of DNA containing short repetitions 
of base sequences that allow bacterial cells to 
record DNA sequences of viruses that it has 
been exposed to. This enables cells to bolster 
the immune function of progeny. The Cas9 
enzyme then functions to seek out those bits of 
viral DNA and cut them out of sequence. 
Importantly, the complex is programmable, 
allowing scientists to target and remove spe- 
cific bits of DNA with great precision. The cut-
ting-edge discovery of the CRISPR/Cas9 tech-
nology has propelled scientists forward in 
attempts to treat or cure diseases caused by 
single-gene mutations [13]. Applications of the 
CRISPR/Cas9 complex to mitochondrial dis-
ease have yet to be fully explored.
MRT: a novel approach
Candidates for MRT
After birth, there are currently no curative ther-
apies for diseases caused by mtDNA muta-
tions. While mild disease as a result of mtDNA 
mutations in mothers does not seem to have a 
profound effect on fertility, there is a significant 
risk of the defect being passed to the child. 
According to data from the Medical Research 
Council (MRC) Mitochondrial Disease Cohort 
U.K. in 2011, it was estimated that 2473 
women were at risk for transmitting mtDNA dis-
ease nationally. Based on national fertility 
rates, it was estimated that the average num-
ber of births per year among the high risk 
women is 152 in the United Kingdom [14]. 
Using midyear 2012 data for women in the 
same age group in the United States, it was 
extrapolated that 12,423 women are at risk for 
transmitting mitochondrial disease, resulting in 
nearly 778 births per year in the United States 
that could potentially benefit from treatment 
[14]. In the absence of transmission preven-
tion, the increasing number of affected females 
will cause an even greater number of individu-
als to be affected in the next generation.  
As previously mentioned, mothers can be either 
homoplasmic or heteroplasmic carriers of mito-
chondrial disease. Mitochondrial disease is 
usually seen in individuals carrying mutant 
mtDNA loads of greater than 60% [3]. Homo- 
plasmy presents a greater challenge, due to 
the complete lack of healthy wild-type mtDNA. 
For heteroplasmic individuals, in vitro mtDNA 
therapy is thought to be effective, though per-
haps more so in younger mothers. Current 
research suggests that as women age, they 
acquire an increasing number of de novo muta-
tions in germline tissues [15]. The level of 
heteroplasmy can also change drastically from 
one oocyte to another due to genetic drift and 
a lack of uniform separation of cytoplasmic 
material during oogenesis in the germline 
bottleneck phenomenon. This can lead to a 
mother who has a relatively low fraction of 
mutated mtDNA and few symptoms giving 
birth to an offspring with a larger fraction of 
mutated mtDNA and a more severe phenotypic 
expression [15]. It can be concluded that 
those with the most to gain from potential 
mtDNA therapies are women of advanced 
maternal age who carry low levels of mutant 
mtDNA in their eggs, though there has been 
much controversy surrounding the proposed 
treatment [3]. More recently, however, it has 
been suggested that MRT will still be able to 
benefit women close to or above disease 
threshold, in contrast to PGD, which requires 
most of the mtDNA to be wild-type [1]. Therefore, 
while MRT has been shown to prevent trans-
mission in mothers with low mutant mtDNA, 
new advancements may make it possible for 
homoplasmic carriers to conceive without 
transmission, a feat no other method has come 
close to achieving. 
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Techniques for MRT
Due to the complexities of altering oocyte 
mtDNA content in vitro, there are currently 
three primary procedures for accomplishing 
this daunting task; metaphase II spindle-chro-
mosome complex (MII-SCC) transfer, pronu-
clear (PN) transfer, and germinal vesicular (GV) 
transfer (Figure 1). In MII-SCC transfer, the 
mature oocyte containing mutant mtDNA is 
progressed to metaphase II where the chromo-
somal material is arranged along the meta-
phase plate. Subsequently it can be harvested 
and implanted into a healthy, enucleated donor 
oocyte (Figure 1A). This technique allows for 
the newly constructed oocyte to be fertilized by 
a viable sperm after the transfer occurs, but 
due to the nebulous nature of the spindle com-
plex, carries the risk of extracting more cyto-
plasm and increasing the amount of mutated 
mtDNA that is concomitantly transferred [16]. 
PN transfer is the process by which the pronu-
clei, the nuclei of the sperm and oocyte before 
they fuse inside the oocyte, are removed from 
the parent zygote and are placed in a donor 
zygote that was previously fertilized and subse-
quently enucleated [3] (Figure 1B). This tech-
nique allows for the extraction of the two, well-
defined pronuclei after the sperm has been 
introduced into the oocyte, potentially reducing 
the amount of cytoplasm that is transferred 
with the pronuclei and decreasing the carryover 
of mutated mtDNA [3]. With this data in mind, 
PN, rather than MII-SCC, transfer may be the 
technique worth pursuing in future studies in 
order to achieve a better outcome in those with 
higher levels of mutant mtDNA. While it is diffi-
cult at this point to compare MII-SCC and PN 
transfer techniques due to lack of meaningful 
concomitant research using the same animal 
model, both have their advantages from a tech-
nical standpoint and perhaps, more important-
ly, show great promise. 
Though these two methods are the most pre-
dominant in the current literature, it is worth 
mentioning that GV transfer, the process of 
transferring a healthy, immature oocyte nucle-
us to an otherwise healthy donor egg, is yet 
another proposed way to reduce the amount of 
inviable mtDNA but there have been fewer stud-
ies on it [17]. 
GV transfer is done during the arrested pro-
phase of meiosis I, when two copies of each of 
the 23 pairs of chromosomes are present. 
Because of the large size of the nucleus at this 
stage, it is easier to successfully harvest in the 
lab. The reconstructed oocyte is then matured 
in vitro prior to fertilization. The maturation of 
the oocyte in vitro allows for surveillance of 
meiosis defects. This may specifically confer 
benefits on women of advanced maternal age, 
who are thought to have reduced pregnancy 
rates associated with aneuploidy, or the uneven 
distribution of chromosomes during meiosis II 
[18]. However, during the harvest of the GV, 
small amounts of residual ooplasm may be 
transferred as well, thus opening the possibility 
of mutated mtDNA being present in the newly 
reconstructed oocyte [19]. In a 2014 study by 
Neupane et al., all three techniques for MRT 
were compared in the same animal model. 
Results showed that the GV transfer method 
was equally as successful as its counterparts 
in excluding mtDNA, with an average level of 
mtDNA carryover of less than 2% [20]. 
Additional studies regarding the comparison of 
these techniques should be pursued to deter-
mine the indication and use guidelines for each 
prior to clinical trials. 
Efficacy
In order to assess the efficacy of these various 
modes of treatment, most research focuses on 
two main quality indicators, namely the level of 
maternal mtDNA carryover and the develop-
mental potential of the reconstructed oocyte. 
Percentages of mtDNA carryover less than 3% 
are usually considered satisfactory as there will 
be no phenotypic changes observed and the 
chance for recurrence in future generations is 
relatively low. However, rates of mtDNA carry-
over greater than 5% increased the possibility 
of another family member exhibiting the mito-
chondrial disease in later generations [21]. The 
standard for the developmental potential of the 
reconstructed oocyte varies among studies, 
with some considering the progression of the 
fertilized egg to the blastocyst stage a success 
while others consider a viable, live offspring as 
their benchmark.
Two separate studies in 2014 focusing on MRT 
in mice both yielded positive results. A recent 
study by Wang et al. showed that MRT allowed 
for normal development of progeny within the 
normal weight range like that of the control 
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Figure 1. Schematic of three different transfer methods for MRT. A. In pronuclear transfer, fertilization occurs first and the resulting zygote’s male and female pronu-
clei is transferred to another enucleated zygote. B. In spindle transfer, the nuclear genetic material from an oocyte containing mutated mtDNA is transferred over to 
an enucleated oocyte containing healthy mtDNA and is subsequently fertilized. C. In germinal vesicle transfer, the nuclear genetic material from an oocyte containing 
mutated mtDNA is harvested earlier in the cell cycle, transferred over to a donor oocyte, and then matured in vitro prior to fertilization and implantation (adapted 
from Mitalipov et al., 2014; Neupane, 2014). 
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group [22]. The same study also showed that 
most offspring exhibited low levels of mtDNA 
carryover (under 6.88%), with the notable 
exception being the progeny coming from PN 
transfer, which showed heteroplasmy in the 
wide range of 5.55%-39.8%. A second study by 
Neupane et al. produced similar results with 
regard to developmental potential showing that 
embryonic development up to the blastocyst 
stage was nearly identical in both MII-SCC and 
PN transfer and the quality of the blastocyst 
itself was comparable to the controls. With 
regard to mtDNA carryover, 21 out of 25 cases 
showed no detectable mtDNA carryover and 
the remaining four cases showed only small 
amounts of mtDNA (<3% heteroplasmy) [20]. 
While GV transfer was shown to be as effective 
as PN and MII-SCC transfer in terms of exclud-
ing mutated maternal mtDNA, it lagged in effi-
cacy. Despite the success in transferring GV 
nuclei, embryonic development faltered during 
the in vitro maturation process and all of the 
samples failed to reach the blastocyst stage 
[20].
In a 2009 study, Tachibana et al. evaluated the 
efficacy of MRT using MII-SCC transfer in pri-
mates, garnering positive results [17]. The 
study reported heteroplasmy levels in the newly 
reconstructed oocytes of less than 3%, which 
was the lowest threshold that could be detect-
ed by their lab [17]. Once the oocytes were fer-
tilized and matured to the blastocyst stage, 
they were implanted in a female surrogate. Of 
the six females receiving implantations, three 
became pregnant and at the time of publica-
tion, two of the mothers had given birth, a pair 
of twins and a singleton. All three babies were 
healthy with pregnancy parameters, such as 
birth weight and the length of gestation, within 
normal ranges for the species [17]. 3-year 
follow up studies of the offspring showed nor-
mal growth, development, and overall health 
as compared to age-matched controls, thus 
providing “convincing evidence that oocyte 
manipulation and mtDNA replacement proce-
dures are compatible with normal develop-
ment” [16]. 
Trials using human oocytes in 2010 were large-
ly successful, with the mean mtDNA carryover 
staying well under 2% for all embryos, which is 
consistent with the controls [3]. No substantial 
difference was found in the amount of mtDNA 
carryover between MII-SCC and PN transfer, 
suggesting that both approaches are equal in 
efficacy [3]. Due to ethical considerations, it 
is difficult to assess the developmental poten-
tial of these human embryos beyond the 
blastocyst stage. It is also worth noting that 
many studies cite concerns about whether the 
amount of heteroplasmy found in samples of 
blastocyst and trophectoderm are representa-
tive of the embryo as a whole.
In research, three species (human, mice and 
primates) have been shown a very high rate of 
efficacy for both MII-SCC and PN transfers [23]. 
Trials were successful in producing offspring, 
whether in the form of a viable blastocyst 
(human embryos) or a viable neonate (mice and 
primate embryos), with levels of heteroplasmy 
ranging from less than 2% in humans [3] and as 
high as 6.88% in mice [22]. With the exception 
of the 2014 Wang et al. study, which found 
higher rates of heteroplasmy in the PN transfer 
than MII-SCC transfer, all studies consistently 
showed that while both techniques are suc-
cessful, lower levels of heteroplasmy were 
found in PN transfer. This is most likely due to 
the lower rates of cytoplasm transfer in PN 
transfer. At less than 2%, human embryo trials 
showed the lowest rates of mtDNA carryover, 
thus supporting further research into the effi-
cacy of MRT in human, full-term trials. 
Furthermore, additional research on PN trans-
fer should be pursued in order to fine-tune the 
technique to prevent transmission in patients 
having higher mutant mtDNA loads.
CRISPR/Cas9
The CRISPR/Cas9 technology has exploded in 
popularity because of its affordability and 
potential applications in curing genetic disease. 
In the last few years, several animal studies 
have been published demonstrating its power-
ful gene editing capabilities. In a 2014 study by 
Yin et al., CRISPR/Cas9 mediated gene-editing 
was demonstrated to be possible in adult ani-
mals, and was curative for the hereditary, sin-
gle-gene mutation condition tyrosinemia, 
despite changing only 6% of cells [24]. This is 
reason enough to be curious about the curative 
potential for both heteroplasmic and homo-
plasmic mtDNA mutation carriers - while the 
gene-editing may not affect all mtDNA, it may 
modify enough to bring the individual below the 
disease threshold, conferring therapeutic 
benefits.
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Other studies have examined the effectiveness 
of CRISPR/Cas9 in treating single gene disor-
ders such as Duchenne muscular dystrophy, as 
well as eye conditions like retinitis pigmentosa 
and Leber congenital amaurosis (LCA) [25, 26]. 
Corporate research companies such as Editas 
suggest that the first human clinical trials using 
CRISPR/Cas9 will aim to treat LCA and may 
begin as early as 2017. The eye presents an 
ideal testing location, as it is contained, immu-
nologically isolated from the rest of the body, 
easily monitored externally, and can be mea-
sured using established standards of function. 
CRISPR/Cas9 technology has the potential for 
use in diseased individuals, as well as IVF 
embryos prior to implantation. In the case of 
diseased individuals, CRISPR/Cas9 offers the 
“promise” of reducing the mutation load, which 
may subsequently reduce symptoms and the 
burden of disease. Application of CRISPR/Cas9 
therapy with adult patients is less controversial 
than its use with embryos, as adults are able to 
provide informed consent. Furthermore, many 
patients with incurable diseases and compro-
mised quality of life are eager to participate in 
clinical trials of new therapies, as there are no 
viable alternative treatments and it offers hope 
for a cure [27].
In a 2015 study by Liang et al. that was the first 
of its kind, CRISPR/Cas9 was used on tripro-
nuclear (3PN) zygotes to better understand its 
effects in preimplantation embryos [28]. While 
targeting the β-globin gene (HBB), the CRISPR/
Cas9 complex also produced off-target effects. 
Additionally, the efficacy of homologous recom-
bination directed repair of HBB was low and 
produced mosaic embryos. In several of the 
3PN zygotes, there were high rates of DNA 
repair using endogenous sequences instead of 
the therapeutic template [28]. This is a major 
obstacle that must be overcome if the CRISPR/
Cas9 system is to be used therapeutically. 
CRISPR/Cas9 editing of embryonic mtDNA may 
appeal as a more socially-acceptable alterna-
tive to “three-parent IVF”. Instead of combining 
the genetics of three individuals, this technique 
may enable a couple to conceive without requir-
ing donor genetic material. Another advantage 
of trying to treat mitochondrial disease before 
implantation is the small number of cells; it may 
be easier to ensure a reduced mutation load if 
the embryo is in the 8- or 16-cell stage than 
when there are exponentially more cells after 
birth.
While the CRISPR/Cas9 technology has great 
potential in treating genetic disease, more 
research is needed before the science commu-
nity begins human clinical trials. Researchers 
must overcome a number of obstacles, such as 
the reaction of the human immune system, effi-
cient modes of delivery, determining how to 
ensure that a corrected copy of DNA is inserted 
into the sequence, safeguarding against Cas9 
proteins cutting at incorrect loci, and under-
standing and controlling off-target effects [26]. 
Ethical concerns
Like many potential treatments before it, MRT 
raises several ethical concerns, both in theory 
and practice. These concerns have become 
barriers to furthering research and developing 
clinical studies to test the efficacy of MRT in 
humans. Issues from risks to donors and chil-
dren, as well as the fear that this would lead us 
down a slippery slope to “designer” babies, 
have raised important questions that must be 
addressed before this technology can be 
applied.
Tri-Parental offspring: definition and 
consequences
MRT has often been controversially termed 
“three-parent IVF” with the resultant offspring 
being called tri-parental offspring by the media 
and the scientific community at large. Prior to 
MRT being developed, the term tri-parental off-
spring had only been applied to a form of bacte-
rial conjugation and therefore a proper scientif-
ic definition has not been established for 
humans [29]. It is also worth mentioning that 
donor eggs have commonly been used with 
assisted reproductive technology to help 
women without competent oocytes become 
pregnant. In those cases, offspring contain 
genetic material from the oocyte donor and the 
father, but are also influenced in utero by epi-
genetic factors from the carrier mother. Despite 
the molecular contribution of three individuals 
to the offspring, this has not been dubbed 
“three-parent IVF”.
Those that claim that MRT should not be con-
sidered three-parent-IVF point to the fact that 
mtDNA codes only 37 genes (13 proteins, 22 
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tRNAs, and 2 rRNAs) making up just 0.1% of the 
total DNA [30]. Furthermore, mtDNA haplo-
types have little variance amongst the human 
population, which deepens the argument for 
those claiming that the name three-parent-IVF 
is a harmful misnomer [30]. Cytoplasm donors 
are considered as organ donors, and ethical 
researchers concluded that mitochondrial 
donation “does not indicate, either biologically 
or legally, any notion of the child having either a 
third parent or second mother” especially when 
socioeconomic and cultural definitions of par-
enthood are taken into account [29, 30, 32]. 
Furthermore, just as organ donors have no 
claim on the donated organs, cytoplasm donors 
have no claim on the donated organelles and 
by extension any children that receive those 
organelles.  
Additionally, oocyte donors are routinely 
required to sign various release and consent 
forms relinquishing all parental claims to the 
offspring, prior to donation. Furthermore, 
despite the 50% contribution of the donor to 
the genetic material of the offspring, there has 
not been a single case in the U.S. where an egg 
donor has later been granted parental status 
following formally giving up rights to eggs and 
resulting offspring [33]. Based on this prece-
dent, and the incrementally smaller fraction of 
genetic material donated, cytoplasm donors 
should have no realistic expectation of parental 
claim.  
On the other side of the argument, the exis-
tence of any traceable genetic material at all, 
even just 0.1%, may be considered significant 
enough to warrant the importance of the donor 
as a third parent in the equation. Because a 
person’s identity is shaped by who they are and 
how they interact with the world, a disease that 
person may carry also forms part of that iden-
tity. As successfully avoiding passing on a mito-
chondrial disease changes a person’s life, the 
addition of a mtDNA donor in IVF may drasti-
cally change the potential identity of a person. 
For this reason, it is argued that the third per-
son’s genetic material is much more important 
than what detractors say and cannot be simply 
dismissed as providing just 0.1% of the genetic 
material [34]. However, we believe that the 
donated mtDNA would promote a positive 
change of identity in terms of health outcomes, 
rather than create a negative change in the 
form of the identity crisis of having three par-
ents. While a definition of what makes a three-
parent offspring has not been agreed upon, it is 
reasonable to conclude that socially, legally, 
and 99.9% genetically, the parents that are 
receiving the oocyte donation are responsible 
for the child.
Harm to cytoplasm donors
When looking at the risk-benefit ratio for 
donors, ethical issues arise because the ratio 
appears skewed. The benefits to the donor are 
a positive feeling from altruism and financial 
payment (which is controversial in and of itself 
during studies) with many more harms. Risks to 
those donating include daily hormonal injec-
tions and added stress from the relatively inva-
sive procedure. The hormonal injections can 
lead to side effects such as pain, nausea, organ 
damage, infertility, hemorrhage, and cancers 
[34]. The process of hormone injection and sev-
eral oocyte retrievals also raises the risk for 
ovarian hyperstimulation syndrome, which can 
result in death in rare cases [31]. While normal-
ly a risk-benefit ratio such as this can be over-
looked when trying to bring a healthy baby into 
the world, it becomes harder to do so when a 
person is taking the risk for someone else’s 
reproductive goals rather than their own [34]. 
Despite this, it can be argued that as long as 
the donor is aware of all of these risks and con-
sents to the procedure knowing that the donat-
ed material may be used to conceive a child, 
then it is ethical. Additionally, as knowledge of 
the practice expands, siblings, relatives, or 
close friends may wish to donate oocytes spe-
cifically to a couple. These donors especially 
may derive more benefit from supporting the 
reproductive goals of their loved ones, further 
shifting the risk-benefit ratio. Donors have their 
own reasons for donating their oocytes to such 
causes and they are able to better understand 
their own risk-benefit ratios after having the 
MRT technique explained to them in full. 
Impact on offspring and future generations
Another ethical obstacle for starting MRT trials 
is that there is very little long term research into 
how such a procedure will affect the offspring 
and subsequent generations. For example, 
MRT can “affect highly co-ordinated mitochon-
drial-nuclear allelic interactions that have 
become optimized over evolutionary time” [31]. 
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This may require matching donor oocytes to 
compatible patients. Additionally, possible epi-
genetic changes are also a concern, as mtDNA 
replacement’s effects on epigenetic program-
ming are still not known. Long term research 
may be the only way to understand downstream 
effects on subsequent generations; however, 
long term research will not be able to provide 
evidence-based guidance for best practices in 
a reasonable time frame. The concerns of epi-
genetic influence, allelic interactions, and 
health of subsequent generations should be 
investigated with further research using animal 
models to glean more information.
Moving this research from the bench to the 
clinic requires the determination of a favorable 
risk-benefit ratio. However, it is difficult to deter-
mine when a favorable ratio is reached due to 
several unknown factors that cannot be prop-
erly measured at the bench and could only be 
potentially elucidated when the research is 
moved to the clinic. Furthermore, unlike other 
potential studies, it is not the parent that faces 
the risk, but the unborn child [35]. The response 
to this may be to just start human trials, as the 
unknowns of risk-benefit are what first time tri-
als are about. Nevertheless, the risk to children 
and future generations may be argued to be too 
great, especially when there are alternatives 
available, such as adoption, egg donation, and 
prenatal diagnosis paired with abortion [34]. 
However, offering alternatives such as adoption 
and egg donation provide little consolation to 
high risk parents wishing to conceive geneti-
cally related offspring, and also constitutes dis-
regard for patient autonomy. 
The challenge of determining risk-benefit ratio 
is best addressed by using more animal models 
and following at least two future generations of 
those animals. If the animal models show that 
the procedure is safe and without downstream 
effects, then human trials following the chil-
dren throughout their lives should be the next 
step, with the consent of all parties involved. 
Slippery slope and harms to society
By far, one of the biggest ethical concerns for 
MRT is the “slippery slope” argument and the 
fear of playing God by changing mtDNA; that it 
is only a matter of time before we start chang-
ing nuclear DNA and eventually start creating 
“designer” babies. By their very nature, MRT 
techniques change the heritable genetic infor-
mation of an individual, and many critics believe 
that tampering with germline genetic informa-
tion is unethical. Some may argue that this 
would deprive future generations of their right 
to receive an unmanipulated gene pool. The 
fear is that once society reaches the point 
where altering mtDNA is not an issue, it will not 
be long until we pursue other germline modifi-
cations to enhance humans and affect the 
gene pool; it will seem like a small step rather 
than a large one. This, however, is an example 
of an inherently weak “slippery slope” argu-
ment [36]. It is not reasonable to believe that 
preventing mitochondrial disease via MRT will 
inevitably lead to the pursuit of germline modi-
fications for enhancement of healthy embryos. 
Like many arguments of this nature, it is specu-
lative and can be staved off via internal and 
external monitoring systems so that labs keep 
within the proper bounds [31, 34, 37]. 
Benefitting the few
With all the controversies facing it, perhaps the 
procedure would get more support if it affected 
a larger number of lives. In the U.K. for exam-
ple, the number of women with mitochondrial 
defects is 3,500. This number can be further 
divided as mitochondrial defects can be due 
just a mtDNA mutation or a combination of 
mtDNA and nuclear DNA mutations. There are 
disagreements within the scientific community 
about how many patients would benefit from 
the therapy. While Ishii estimates that mtDNA 
replacement IVF could save only about 10 chil-
dren per year in the U.K., Gorman et al. put the 
estimate at 152 births per year in the U.K. 
When considering the bioethical tenet of benef-
icence, the procedure is worth pursuing if it can 
improve lives, even if only helping a small num-
ber of people [14, 31, 38, 39]. 
The medical community has considered the 
ethical aspects of researching and treating rare 
disease, which highlights the conflict between 
beneficence and distributive justice. Based on 
utilitarian theories of justice, some argue that 
society should allocate resources in a way that 
maximizes benefit to the greatest number of 
people, and thus rare diseases are not worth 
the investment [38]. “On the other hand, many 
would uphold that society has a moral obliga-
tion not to abandon individuals who have had 
the bad luck to be affected by a serious but 
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rare condition for which no treatment exists” 
[38]. Several professional bodies in the medi-
cal community, such as the Royal College of 
Physicians, have acknowledged a professional 
duty to promote the advancement of medical 
knowledge and push the envelope of current 
medical treatment. Ultimately, the medical 
community has a basic moral commitment to 
not abandon those in need of “highly special-
ized health care…even in resource constrained 
settings” [38]. It can be argued that the pursuit 
of MRT and related gene therapies is a respon-
sibility that falls upon physicians and research-
ers as stewards of medicine [39]. 
CRISPR/Cas9 vs. MRT
CRISPR/Cas9 avoids the pitfalls and ethical 
concerns seen with MRT since it does not 
require a third person to donate any form of 
genetic material. This avoids the three-parent 
dilemma previously mentioned. Additionally, 
the CRISPR/Cas9 process edits the mtDNA at 
the blastocyst stage of the embryo, the same 
stage where preimplantation diagnosis is being 
performed.
Safety issues
As a new technology, CRISPR/Cas9 has many 
obstacles to overcome, especially before it can 
be used on human embryos. For this reason, 
voluntary moratoriums have been proposed on 
the use of CRISPR/Cas9 on human embryo 
until safety concerns can be assuaged through 
testing on animal embryos. However, these 
moratoriums are voluntary and thus there is no 
enforcement to follow it [40]. Many in the sci-
ence community believe that the 2015 study by 
Liang et al. violated the spirit of this moratori-
um by using human 3PN zygotes [41]. 
The biggest safety concern is precision. As 
Lander points out, the Liang et al. study done 
on human tripronuclear zygotes resulted in 
numerous problem such as incomplete editing, 
inaccurate editing, and off-target mutations 
due to the inaccuracy of CRISPR/Cas9 [42]. 
This is due to the system potentially altering 
DNA locations other than the target, resulting in 
inactivation of essential genes, activation of 
pro-oncotic genes, or rearrangement of chro-
mosomes. Additionally, CRISPR/Cas9 therapy 
may carry the risk of genetic mosaicism, if it is 
unable to affect all cells uniformly [43]. The 
solution to that may be to increase the amount 
of nuclease used, as it may increase how many 
mutated genes are corrected; however, the end 
result could instead increase alteration of the 
wrong gene sequences [44].
It is reasonable to posit that until the technolo-
gy has become safer and more precise, human 
embryo studies should not be done. Like all 
new techniques, CRISPR/Cas9 will only grow 
more refined as research progresses. Once the 
precision of CRISPR/Cas9 comes close to that 
of other techniques approved for use on human 
embryos, it would become acceptable from a 
safety standpoint to move forward with human 
embryo studies.  
Are we ready to change the germline?
As of now, CRISPR/Cas9 has only been used in 
humans on somatic cells. In addition to the 
aforementioned safety concerns about using 
CRISPR/Cas9 on germline cells, there are also 
ethical considerations to changing the germ-
line. Some believe that without knowing the 
downstream effects for future generations, it is 
unethical and too risky to proceed. However, 
since mitochondria account for such a small 
amount of a person’s genetic material, the ram-
ifications of changing the mtDNA would proba-
bly not be as significant as changing chromo-
somal DNA. Alternatively, because only females 
pass on their mitochondria to the next genera-
tion, a proposed solution to avoid future gener-
ations inheriting altered mtDNA is to only alter 
the mtDNA of male embryos. While this pro-
posed solution offers a way to proceed without 
changing the germline, it denies the potentially 
curative technology to families and female 
embryos on the basis of sex. This violates the 
Code of Ethics promulgated by the American 
Medical Association, which states that physi-
cians cannot refuse to care for potential 
patients based on gender or other criteria that 
constitute “invidious discrimination” [45]. 
As illustrated by Darnovsky and Lanphier et al., 
some believe that once the medical community 
starts using the CRISPR/Cas9 technology for 
therapeutic reasons, such as with mitochon-
drial disease, it would be logical to expand to 
other medical uses, like removing identified 
genes for fatal conditions [37, 44]. In addition 
to those objectively beneficial uses of CRISPR/
Cas9, it could be reasonably argued that remov-
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ing risk genes for cancers and other conditions 
would be a benefit to society in the long run. 
However, once the scientific community begins 
to feel comfortable altering genes that do not 
have an immediate impact on the vitality of an 
embryo, progressing to non-therapeutic genetic 
enhancements may follow, leading to “design-
er” babies [44]. This is especially concerning 
since the effects of these changes are not 
know for future generations that inherit these 
genes. 
The biggest worry is that it will lead to a second 
coming of the eugenics movement, which was 
defined by its false ideas that criminal activity 
and low intelligence were inherited genetically, 
an idea the Nazi movement perpetuated to 
the extreme. If CRISPR/Cas9 were to become 
common practice to edit genes for genetic 
enhancement, the fear is that eventually those 
that choose not to or cannot afford the tech- 
nology would be stigmatized [43]. As with MRT, 
the best solution for this would be monitoring 
and laws against using CRISPR/Cas9 for 
enhancements. 
Future of IV mitochondrial genetic therapy
In 2011, the U.K. government asked the Human 
Fertilization and Embryology Authority (HFEA) 
to determine the efficacy and safety of mito-
chondrial gene replacement therapy. The HFEA 
concluded that there is no evidence that sup-
ports either maternal spindle transfer or pro-
nuclear transfer to be unsafe, and that this 
method is suitable for specific circumstances 
in which patients would like to produce geneti-
cally-related offspring without transfer of mito-
chondrial disease [46]. On February 3, 2015 
the U.K. was the first country to approve MRT 
[47]. BBC news reported that by November 24, 
2015 clinics would be able to apply for licenses 
to perform IV mitochondrial replacement and 
this technique could be performed before the 
new year [47]. This major change in legislature 
has been widely debated due to the aforemen-
tioned ethical concerns; 11 days after the 
House of Lords voted to approve three-parent 
IVF, a minority stronghold attempted to block 
the change in legislature [47]. Although the 
attempt failed, this quick response shows the 
magnitude of the controversy surrounding this 
technique. In the upcoming year, this change in 
legislature will not only cause a push for more 
research regarding the safety and efficacy of IV 
mitochondrial replacement before clinic licens-
ing for the procedure takes place, but will also 
pave the way for additional research on apply-
ing this technique in the clinic. Because MRT is 
now legal, more donor oocytes and/or zygotes 
will be used for this research. The supply of 
donor eggs can be obtained through good will 
or perhaps an exchange program, in which 
those undergoing MRT will donate some of their 
eggs to MRT research, although donation rais-
es ethical issues and requires more regulations 
to be set [46]. Following in the footsteps of the 
U.K., the US has demonstrated more willing-
ness to consider the technique for use, as is 
evident by the US Food and Drug Administration 
(FDA) recently mentioning the use of enucleat-
ed donor embryos to solve problems of infertil-
ity among older women [48]. While it continues 
to stir up ethical concerns, change in U.K. legis-
lature allowing MRT has the potential to revolu-
tionize the way we treat both mitochondrial dis-
ease transmission and infertility.
Conclusion
While there is no current cure for mitochondrial 
disease, MRT shows great potential in preven-
tion of transmission. Heteroplasmic carriers 
well below threshold will benefit the most from 
MRT; however, as future research progresses, 
this technique has the potential to be effective 
in those carrying high loads of mutant mtDNA. 
This is a ground-breaking technique because 
there is currently no effective method of pre-
vention for those carrying loads close to or 
greater than threshold. MII-SCC and PN trans-
fer are the primary methods of MRT, but addi-
tional studies need to be performed to highlight 
the differences between the two, and when is 
best to use each method. However, it is clear 
that PN transfer has potential to limit the 
amount of cytoplasm transferred between 
embryos, and is therefore a good approach to 
reduce risk among higher level mutant mtDNA 
carriers. There have been concerns that biop-
sied results from blastomeres in human embry-
os may not be representative of the entire 
fetus, especially as ethical concerns have pre-
vented testing at later stages of embryonic 
development. Despite these concerns, safety 
and efficacy studies using mice, primates, and 
human oocytes have shown positive results, 
suggesting that MRT has not yet been shown to 
be unsafe. 
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While many ethical dilemmas still exist, a com-
bination of strong research results, proper con-
senting methods, and strict guidelines can 
address those issues. Doing so will create 
strong oversight that could put these argu-
ments to rest and lead to happier, healthier 
families.      
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